Eder L, Croxford R, Drucker AM, et al. - The results of this study demonstrated that individuals across all immune-mediated inflammatory diseases (IMIDs) were more likely to be tested for SARS-CoV-2 vs those without IMIDs. In this study, the risk of SARS-CoV-2 infection varied across disease sub-groups.

• Researchers examined 493,499 individuals with IMIDs and 2,466,946 patients without IMIDs.

• The results showed that individuals with IMIDs were more likely to have at least one SARS-CoV-2 test, vs patients without IMIDs (27.4% vs. 22.7%), but the proportion testing positive for SARS-CoV-2 was identical (0.9% in both groups). It was shown that IMIDs individuals had 20% higher odds of being tested for SARS-CoV-2 (odds ratio (OR) 1.20, 95% CI 1.19, 1.21).

• The results showed that odds of SARS-CoV-2 infection varied across IMIDs groups but was not significantly increased for most IMID groups in comparison with non-IMIDs.

• In inflammatory bowel disease and multiple sclerosis, the odds of SARS-CoV-2 infection were lower, while marginally higher in RA and iritis.